Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.40 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244625 | 0.88 | NAAA (0.50) | HRH1SLC6A4SLC6A3SLC6A2CHRNB2 | |
| SCHEMBL242185 | 0.88 | HRH1 (0.50) | HRH1SLC6A4SLC6A3SLC6A2CARM1 | |
| SCHEMBL29856 | 0.84 | HRH1 (0.71) | HRH1SLC6A4SLC6A3SLC6A2CARM1 | |
| Ammonia Solution, Strong SCHEMBL8078606 | 0.81 | HRH1 (0.68) | HRH1SLC6A4SLC6A3SLC6A2CARM1 | |
| SCHEMBL2957422 | 0.81 | PARP10 (0.42) | HRH1 | |
| SCHEMBL3116000 | 0.81 | EPHX2 (0.39) | HRH1CHRNB2CHRNA4EPHX2 | |
| SCHEMBL2102905 | 0.80 | SLC6A2 (0.45) | HRH1SLC6A4SLC6A3SLC6A2CARM1 | |
| SCHEMBL796490 | 0.79 | HRH1 (0.65) | HRH1SLC6A4SLC6A3SLC6A2CARM1 | |
| SCHEMBL1829827 | 0.79 | HRH1 (0.65) | HRH1SLC6A4SLC6A3SLC6A2CARM1 | |
| SCHEMBL3126722 | 0.79 | EPHX2 (0.46) | FPR2PROKR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3921320-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | claimed |
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2022-04-21 | — | — | US | claimed |
| EP-3921320-A1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BeiGene, Ltd. (KY) | 2021-12-15 | — | — | EP | claimed |
| CN-113454086-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2021-09-28 | — | — | CN | claimed |
| WO-2020160711-A1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE, LTD. (KY) | 2020-08-13 | — | — | WO | claimed |
| US-20130245064-A1 | NOVEL NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-09-19 | — | — | US | claimed |
| EP-2635554-A2 | NOVEL NEUROTRYPSIN INHIBITORS | Neurotune AG (CH) | 2013-09-11 | — | — | EP | claimed |
| US-8232271-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-07-31 | — | — | US | claimed |
| WO-2012059443-A2 | NOVEL NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | claimed |
| EP-2350007-A1 | HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | claimed |
| EP-1667980-A1 | 1,4-DISUBSTITUTED ISOQUINOLINE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2006-06-14 | — | — | EP | claimed |
| WO-2005028444-A1 | 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | claimed |
| EP-0644878-B1 | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-09-12 | — | — | EP | claimed |
| US-5712272-A | TREATMENT OF NEUROLOGICAL DISORDERS WITH BENZ(B)AZEPINE COMPOUNDS | ZENECA LIMITED (GB) | 1998-01-27 | — | — | US | claimed |
| US-5654295-A | NEUROLOGICAL DISORDERS; BENZ(B0AZEPINE COMPOUNDS | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | claimed |
| US-5492905-A | NERVOUS SYSTEM DISORDERS | ZENECA LIMITED (GB) | 1996-02-20 | — | — | US | claimed |
| EP-0577470-B1 | 2-Amino-N-[[[4-(aminocarbonyl)pyrimidin-2-yl]amino]alkyl]-pyrimidine-4-carboxamide derivates, their preparation and their use in therapeutics | SYNTHELABO (FR) | 1995-05-24 | — | — | EP | claimed |
| EP-0644878-A1 | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS | ZENECA LIMITED (GB) | 1995-03-29 | — | — | EP | claimed |
| US-5330985-A | Adrenergic blocking agents; urogenital disorders | SYNTHELABO (FR) | 1994-07-19 | — | — | US | claimed |
| WO-1993025534-A1 | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR3 | HRH1 299/4885SLC6A4 2203/4885SLC6A3 2487/4885 |
| US-20130245064-A1 | NOVEL NEUROTRYPSIN INHIBITORS | PRSS12, NLN, MTPN | HRH1 720/4885SLC6A4 2163/4885SLC6A3 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.